Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 45

1.

Neuronal Surface Autoantibodies in Neuropsychiatric Disorders: Are There Implications for Depression?

Zong S, Hoffmann C, Mané-Damas M, Molenaar P, Losen M, Martinez-Martinez P.

Front Immunol. 2017 Jul 5;8:752. doi: 10.3389/fimmu.2017.00752. eCollection 2017. Review.

2.

Expressing acetylcholine receptors after innervation suppresses spontaneous vesicle release and causes muscle fatigue.

Mott M, Luna VM, Park JY, Downes GB, Epley K, Ono F.

Sci Rep. 2017 May 10;7(1):1674. doi: 10.1038/s41598-017-01900-3.

3.

Dysregulation of B Cell Repertoire Formation in Myasthenia Gravis Patients Revealed through Deep Sequencing.

Vander Heiden JA, Stathopoulos P, Zhou JQ, Chen L, Gilbert TJ, Bolen CR, Barohn RJ, Dimachkie MM, Ciafaloni E, Broering TJ, Vigneault F, Nowak RJ, Kleinstein SH, O'Connor KC.

J Immunol. 2017 Feb 15;198(4):1460-1473. doi: 10.4049/jimmunol.1601415. Epub 2017 Jan 13.

PMID:
28087666
4.

Commentary on "Randomized trial of thymectomy in myasthenia gravis".

Tzankov A.

J Thorac Dis. 2016 Oct;8(10):E1420-E1422. No abstract available.

5.

Compromised fidelity of B-cell tolerance checkpoints in AChR and MuSK myasthenia gravis.

Lee JY, Stathopoulos P, Gupta S, Bannock JM, Barohn RJ, Cotzomi E, Dimachkie MM, Jacobson L, Lee CS, Morbach H, Querol L, Shan JL, Vander Heiden JA, Waters P, Vincent A, Nowak RJ, O'Connor KC.

Ann Clin Transl Neurol. 2016 Apr 27;3(6):443-54. doi: 10.1002/acn3.311. eCollection 2016 Jun.

6.

Clinical Profile and Outcome of Postthymectomy versus Non-Thymectomy Myasthenia Gravis Patients in the Philippine General Hospital: A 6-Year Retrospective Study.

De Roxas RC, Bagnas MA, Baldonado JJ, Rivera JP, Roxas AA.

Front Neurol. 2016 Jun 21;7:96. doi: 10.3389/fneur.2016.00096. eCollection 2016.

7.

Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms.

Phillips WD, Vincent A.

F1000Res. 2016 Jun 27;5. pii: F1000 Faculty Rev-1513. doi: 10.12688/f1000research.8206.1. eCollection 2016. Review.

8.

Animal models of myasthenia gravis: utility and limitations.

Mantegazza R, Cordiglieri C, Consonni A, Baggi F.

Int J Gen Med. 2016 Mar 4;9:53-64. doi: 10.2147/IJGM.S88552. eCollection 2016. Review.

9.

The potential role of cell surface complement regulators and circulating CD4+ CD25+ T-cells in the development of autoimmune myasthenia gravis.

Hamdoon MN, Fattouh M, El-Din AN, Elnady HM.

Electron Physician. 2016 Jan 15;8(1):1718-26. doi: 10.19082/1718. eCollection 2016 Jan.

10.

Maternal myasthenia gravis: a cause for arthrogryposis multiplex congenita.

Midelfart Hoff J, Midelfart A.

J Child Orthop. 2015 Dec;9(6):433-5. doi: 10.1007/s11832-015-0690-8. Epub 2015 Oct 19.

11.

Adult autologous mesenchymal stem cells for the treatment of suspected non-infectious inflammatory diseases of the canine central nervous system: safety, feasibility and preliminary clinical findings.

Zeira O, Asiag N, Aralla M, Ghezzi E, Pettinari L, Martinelli L, Zahirpour D, Dumas MP, Lupi D, Scaccia S, Konar M, Cantile C.

J Neuroinflammation. 2015 Sep 29;12:181. doi: 10.1186/s12974-015-0402-9.

12.

Neuroinflammation: Ways in Which the Immune System Affects the Brain.

Ransohoff RM, Schafer D, Vincent A, Blachère NE, Bar-Or A.

Neurotherapeutics. 2015 Oct;12(4):896-909. doi: 10.1007/s13311-015-0385-3. Review.

13.

Antigen Presentation, Autoantigens, and Immune Regulation in Multiple Sclerosis and Other Autoimmune Diseases.

Riedhammer C, Weissert R.

Front Immunol. 2015 Jun 17;6:322. doi: 10.3389/fimmu.2015.00322. eCollection 2015. Review.

14.

miR-15b is Downregulated in Myasthenia Gravis Patients and Directly Regulates the Expression of Interleukin-15 (IL-15) in Experimental Myasthenia Gravis Mice.

Shi L, Liu T, Zhang M, Guo Y, Song C, Song D, Liu H.

Med Sci Monit. 2015 Jun 19;21:1774-80. doi: 10.12659/MSM.893458.

15.

Biomechanical strain vehicles for fibroblast-directed skeletal myoblast differentiation and myotube functionality in a novel coculture.

Hicks MR, Cao TV, Standley PR.

Am J Physiol Cell Physiol. 2014 Oct 15;307(8):C671-83. doi: 10.1152/ajpcell.00335.2013.

16.

Neutralization of interleukin-9 ameliorates symptoms of experimental autoimmune myasthenia gravis in rats by decreasing effector T cells and altering humoral responses.

Yao X, Kong Q, Xie X, Wang J, Li N, Liu Y, Sun B, Li Y, Wang G, Li W, Qu S, Zhao H, Wang D, Liu X, Zhang Y, Mu L, Li H.

Immunology. 2014 Nov;143(3):396-405. doi: 10.1111/imm.12322.

17.

Expression of RAGE and HMGB1 in thymic epithelial tumors, thymic hyperplasia and regular thymic morphology.

Moser B, Janik S, Schiefer AI, Müllauer L, Bekos C, Scharrer A, Mildner M, Rényi-Vámos F, Klepetko W, Ankersmit HJ.

PLoS One. 2014 Apr 4;9(4):e94118. doi: 10.1371/journal.pone.0094118. eCollection 2014.

18.

Double seronegative myasthenia gravis with antiphospholipid syndrome: a case report.

Dan D, Bart PA, Novy J, Kuntzer T, Clair C.

J Med Case Rep. 2014 Jan 1;8:2. doi: 10.1186/1752-1947-8-2.

19.

Determinants in the β and δ subunit cytoplasmic loop regulate Golgi trafficking and surface expression of the muscle acetylcholine receptor.

Rudell JC, Borges LS, Rudell JB, Beck KA, Ferns MJ.

J Biol Chem. 2014 Jan 3;289(1):203-14. doi: 10.1074/jbc.M113.502328. Epub 2013 Nov 15.

20.

Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis.

Shen C, Lu Y, Zhang B, Figueiredo D, Bean J, Jung J, Wu H, Barik A, Yin DM, Xiong WC, Mei L.

J Clin Invest. 2013 Dec;123(12):5190-202. doi: 10.1172/JCI66039. Epub 2013 Nov 8.

Supplemental Content

Support Center